Advertisement

Doklady Biochemistry and Biophysics

, Volume 480, Issue 1, pp 158–161 | Cite as

A Universal Tumor-Specific Promoter for Cancer Gene Therapy

  • I. V. Alekseenko
  • V. V. Pleshkan
  • A. V. Sass
  • O. B. Filyukova
  • E. V. Snezhkov
  • E. D. Sverdlov
Biochemistry, Biophysics, and Molecular Biology
  • 4 Downloads

Abstract

An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high activity in tumor cells, which is comparable to the activity of the CMV constitutive promoter.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hsu, C.P., Miaw, J., Hsia, J.Y., Shai, S.E., and Chen, C.Y., Concordant expression of the telomeraseassociated genes in non-small cell lung cancer, Eur. J. Surg. Oncol., 2003, vol. 29, pp. 594–599.CrossRefPubMedGoogle Scholar
  2. 2.
    Poulsen, T.T., Pedersen, N., Juel, H., and Poulsen, H.S., A chimeric fusion of the hASH1 and EZH2promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells, Cancer Gene Ther., 2008, vol. 15, pp. 563–575.CrossRefPubMedGoogle Scholar
  3. 3.
    Farokhimanesh, S., Rahbarizadeh, F., Rasaee, M.J., Kamali, A., and Mashkani, B., Hybrid promoters directed tbid gene expression to breast cancer cells by transcriptional targeting, Biotech. Prog., 2010, vol. 26, pp. 505–511.Google Scholar
  4. 4.
    Kim, H.A., Park, J.H., Yi, N., and Lee, M., Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma- specific gene therapy, Mol. Pharm., 2014, vol. 11, pp. 938–950.CrossRefPubMedGoogle Scholar
  5. 5.
    Alekseenko, I.V., Pleshkan, V.V., Kopantzev, E.P., Stukacheva, E.A., Chernov, I.P., Vinogradova, T.V., and Sverdlov, E.D., Activity of the upstream component of tandem tert/survivin promoters depends on features of the downstream component, PLoS One, 2012, vol. 7, e46474.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kerr, D., Clinical development of gene therapy for colorectal cancer, Nat. Rev. Cancer, 2003, vol. 3, pp. 615–622.CrossRefPubMedGoogle Scholar
  7. 7.
    Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L., and Abraham, G.N., The “bystander effect:” tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 1993, vol. 53, pp. 5274–5283.PubMedGoogle Scholar
  8. 8.
    Mori, K., Iwata, J., Miyazaki, M., Osada, H., Tange, Y., Yamamoto, T., Aiko, Y., Tamura, M., and Shiroishi, T., Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells, Neurol. Med. Chir. (Tokyo), 2010, vol. 50, pp. 545–553.CrossRefGoogle Scholar
  9. 9.
    Yamamoto, S., Yamano, T., Tanaka, M., Hoon, D.S., Takao, S., Morishita, R., Aikou, T., and Kaneda, Y., A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma, Cancer Gene Ther., 2003, vol. 10, pp. 179–186.CrossRefPubMedGoogle Scholar
  10. 10.
    Azatian, A., Yu, H., Dai, W., Schneiders, F.I., Botelho, N.K., and Lord, R.V., Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas, J. Gastrointest. Surg., 2009, vol. 13, pp. 1044–1051.CrossRefPubMedGoogle Scholar
  11. 11.
    Clive, K.S., Tyler, J.A., Clifton, G.T., Holmes, J.P., Mittendorf, E.A., Ponniah, S., and Peoples, G.E., Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?, Expert Rev. Vaccines, 2010, vol. 9, pp. 519–525.CrossRefPubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • I. V. Alekseenko
    • 1
    • 2
  • V. V. Pleshkan
    • 1
    • 2
  • A. V. Sass
    • 1
  • O. B. Filyukova
    • 1
  • E. V. Snezhkov
    • 1
  • E. D. Sverdlov
    • 1
    • 2
  1. 1.Shemyakin–Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia
  2. 2.Institute of Molecular GeneticsRussian Academy of SciencesMoscowRussia

Personalised recommendations